Anti-hPD-L1-hIgG1 features the constant region of the human IgG1 isotype and the variable region of atezolizumab. Atezolizumab (also known as MPDL3280A) is a fully humanized IgG1 (N298A) monoclonal antibody that targets the programmed cell death ligand 1 (PD-L1), a transmembrane protein over-expressed on tumor cells and tumor infiltrating immune cells, such as macrophages. PD-L1 binds to programmed cell death protein 1 (PD-1) on cytotoxic T cells, inhibiting the antitumor immune response [1]. Atezolizumab blocks the interaction of PD-L1 with PD-1 and induces anti-tumor immune reactivation. Atezolizumab contains a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [2, 3]. The mutation N298A eliminates its ability to bind to human Fcγ receptors. FDA has granted atezolizumab priority review for advanced bladder cancer.

Anti-hPD-L1-hIgG1 contains the Fc region of wild-type IgG1. In contrast to the N298A mutant, it displays high CDC and high ADCC.

Anti-hPD-L1-hIgG1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.


Specificity: Targets cells expressing human and mouse PD-L1
Clonality: Monoclonal antibody
Isotype: Human IgG1
Source: CHO cells
Purity: Purified by affinity chromatography with protein G


• 100 µg purified anti-hPD-L1-hIgG1 antibody, provided azide-free and lyophilized


1. McDermott D. & Atkins M. 2013. PD-1 as a potential target in cancer therapy. Cancer Med. 2(5): 662–673.
2. Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
3. Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.



Description Human PD-L1 (atezolizumab) antibody - Human IgG1
Cat. Codehpdl1-mab1
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".